Skip to main content
. 2020 Jul 26;7:100110. doi: 10.1016/j.bbih.2020.100110

Fig. 5.

Fig. 5

Larger LPC-induced demyelinated lesionsare presentin CID treated mice than controls. A. Schematic of the CID injection and the time-line for LPC injections. B. Representative EM images from the ventral regions show no significant differences in the number of myelinated axons and myelin thickness between VEH and CID treated animals at 8 weeks of age. C. Representative images show sections from wild type (WT) mouse injected with saline (WT/-/Saline), MBP-iCP9 transgenic mouse injected with vehicle (VEH) followed by LPC (TG/VEH/LPC), and MBP-iCP9 transgenic mouse injected with CID followed by LPC (TG/CID/LPC). Sections were taken 14 days after LPC injection. WT mice injected with saline did not show any detectable lesion. WT/CID/LPC and TG/VEH/LPC treated mice (Controls) served as control groups in which oligodendrocytes were not ablated. D. The total volume of white matter (WM) area was compared to the total volume of spinal cord across all groups and no significant differences were detected suggesting that normal myelination was unaffected by creation of the transgenic phenotype. Two sections from each animal were assessed and the relative proportion of lesioned dorsal white matter was significantly (p-value ​= ​0.0039) higher in experimental transgenic mice, that had received CID and LPC (n ​= ​3) compared to those that received vehicle and LPC or wild type mice that received CID (n ​= ​2) suggesting slower remyelination in the CID treated transgenic mice (Bar in B ​= ​25 ​μm).